Latest Forecast: Lots to Discuss on Competitive Intelligence at Pharma CI
Somehow it is already September which means we’re preparing for one of the key events in the biopharma calendar, at least if you’re involved in competitive intelligence – and really, who isn’t? The Pharma CI Conference and Exhibition takes place in Newark on 20th and 21st of September and many of the Evaluate and Norstella […]
My Perfect Combination: Customers and Food
At the recent BIO International convention, I was able to combine two of my favourite things – talking to customers and an excellent meal! Somehow, it’s already a month since BIO International. The week in Boston went by in a blur of meetings, conversations and networking but for me, there was one stand-out occasion. […]
Evaluate Omnium: An Award-Winning Decision
Evaluate Omnium is now officially an award-winning solution! Last month, we were delighted to announce that we have won an award. Evaluate Omnium, our machine learning-powered solution was named as Best Decision Management Solution by the AI Breakthrough awards. While we have always been very proud of Evaluate Omnium, and while we know that […]
BioSci Deal of the Month – Kite & Arcellx
In December of 2022, Kite and Arcellx entered an agreement to develop and commercialise Arcellx’s multiple myeloma product candidate CART-ddBCMA. The candidate is currently in Phase 2 clinical development and is a cell therapy product comprising of genetically modified autologous T cells. The collaboration brings together Arcellx’s promising CART-ddBCMA therapy with Kite’s expertise and leadership […]
Five Top Takeaways from BIO International 2023
A couple of weeks ago, we saw the return of BIO International to Boston for the first time since 2018. Since Boston is Evaluate’s home turf in the US, we headed to the gigantic Boston Convention Center to join 19,000 pharma, biotech and investment experts for four days of meetings, presentations, networking shindigs and sore […]
In Case You Missed It: Three Things We Learned In Our Gene Editing Webinar
Missed our gene editing webinar? Fear not! Here are a few of the highlights from our panel of experts which included Verve Therapeutics’ CEO, Sekar Kathiresan as well as our home-grown specialists. And if that’s not enough, the webinar is available on demand. Gene editing is a hot topic right now. With the first Pdufa […]
Five Questions About the Future of Gene Editing
Gene editing has been in and out of the news since Crispr hit the headlines a decade ago. It’s been anything from the next big thing to a borderline miracle to a potential menace. Is it just going through the same growing pains as any new technology in the pharma industry? Or is it fundamentally […]
BioSci Deal of the Month – Spero Therapeutics & GSK
In September of 2022, GSK and Spero Therapeutics entered into an exclusive license agreement for late-stage antibiotic asset, Tebipenem HBr. Tebipenem HBr is an oral carbapenem antibiotic aimed at treating complicated urinary tract infections including pyelonephritis. GSK will receive an exclusive license to develop and commercialise Tebipenem pivoxil and tebipenem pivoxil HBr in all territories […]
In Case You Missed It: Three Things We Learned From Our Orphan Drug Webinar
Missed our webinar on orphan drugs and the impact of the Inflation Reduction Act? Well, you missed a lot but here are a few takeaways to help you catch up. And the full webinar is available on demand. Drugs for orphan indications are a fascinating area of the pharma industry. Our recent report on the […]
BioSci Deal of the Month – Kainos Medicines & Emmaus Life Sciences
In February of 2021, Emmaus Life Sciences and Kainos Medicine entered into an agreement to jointly develop Kainos’ patented IRAK4 inhibitor (KM10544). IRAK4 is a serine-threonine protein kinase known to be present and active in the occurrence of certain immunity responses, inflammation disorders, and various cancers. Under the terms of this agreement, Kainos will study […]
